Roche's Tecentriq Approved As Second-Line in Lung Cancer: Implications For Bristol-Myers Squibb
FDA approved Roche's (U.S. ADR, OTCBB: RHHBY) Tecentriq, a checkpoint inhibitor that targets PD-L1 as a second-line therapy in metastatic non-small...
344 Views
Ono Pharmaceutical - More Bad News As Tecentriq's OAK Trial Goes Well
Roche's US subsidiary, Genentech announced that the OAK trial for Tecentriq met its primary endpoint (a statistically significant and clinically...
347 Views
Fasten Your Belts: Air Pockets Ahead
OBI Pharmaceuticals (4174:TT) is a biotechnology company developing treatments for cancer. The company has been mired in controversy for the past...
284 Views